Click on image to view larger version.

Figure 2 (A) Mean change from baseline in 6-min walk distance (6MWD) for all patients at week 12 for the 1-, 2.5-, 5-, and 10-mg-dose groups and for all dose groups combined. (B) Mean change from baseline in 6MWD for idiopathic pulmonary arterial hypertension patients at week 12 for the 1-, 2.5-, 5-, and 10-mg-dose groups and for all dose groups combined. (C) Mean change from baseline in 6MWD for patients with pulmonary arterial hypertension associated with collagen vascular disease, anorexigen use, or human immunodeficiency virus infection at week 12 for the 1-, 2.5-, 5-, and 10-mg-dose groups and for all dose groups combined. *p < 0.02, p < 0.001, p < 0.03.